INT119729

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2000
Last Reported 2010
Negated 4
Speculated 1
Reported most in Body
Documents 31
Total Number 32
Disease Relevance 24.02
Pain Relevance 7.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Tnfsf11) extracellular space (Tnfsf11) extracellular region (Tnfsf11)
plasma membrane (Tnfsf11) intracellular (Tnfsf11) cytoplasm (Tnfsf11)
Anatomy Link Frequency
osteoclast 6
bone marrow 2
T cell 2
dendritic cell 1
TMJ 1
Tnfsf11 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 402 100.00 Very High Very High Very High
qutenza 3 99.80 Very High Very High Very High
metalloproteinase 40 99.64 Very High Very High Very High
agonist 27 99.60 Very High Very High Very High
Arthritis 555 99.16 Very High Very High Very High
Inflammatory marker 6 98.56 Very High Very High Very High
Inflammation 515 98.16 Very High Very High Very High
rheumatoid arthritis 494 97.24 Very High Very High Very High
dexamethasone 5 93.08 High High
Inflammatory response 5 91.68 High High
Disease Link Frequency Relevance Heat
Hypercalcemia 274 100.00 Very High Very High Very High
Cardiovascular Disease 14 100.00 Very High Very High Very High
Arthritis 460 99.16 Very High Very High Very High
Apoptosis 51 99.12 Very High Very High Very High
Cancer 117 98.52 Very High Very High Very High
INFLAMMATION 509 98.24 Very High Very High Very High
Osteoporosis 273 98.02 Very High Very High Very High
Bone Cancer 49 97.84 Very High Very High Very High
Rheumatoid Arthritis 644 97.24 Very High Very High Very High
Frontotemporal Dementia 2 97.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These chimeric molecules act as decoys by binding to and sequestering RANKL, thus preventing it from interacting with its native receptor on hematopoietic osteoclast precursors and mature osteoclasts.
RANKL Binding (binding) of in osteoclasts
1) Confidence 0.35 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924519 Disease Relevance 0.74 Pain Relevance 0
, IL-8), mediators of bone and cartilage damage such as matrix metalloproteinases and RANK-ligand (RANKL) [4], [5], [6], neutrophil and monocyte recruitment [7], [8], and osteoclastogenesis [9].
RANKL Binding (recruitment) of in monocyte associated with metalloproteinase
2) Confidence 0.35 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2931706 Disease Relevance 1.04 Pain Relevance 0.73
B ligand (RANKL)/receptor activator of nuclear factor (NF)?
RANKL Binding (ligand) of
3) Confidence 0.34 Published 2007 Journal Clinical and Developmental Immunology Section Abstract Doc Link PMC2248226 Disease Relevance 0.82 Pain Relevance 0.12
B; RANK-L, RANK-ligand; OPG, osteoprotogerin; VCP, valosin-containing protein; UPS, ubiquitin proteasome system; IKKß, I-?
OPG Binding (ligand) of
4) Confidence 0.32 Published 2007 Journal BMC Biochem Section Body Doc Link PMC2106369 Disease Relevance 1.12 Pain Relevance 0.08
The reduced levels of OPG in bone marrow of patients with myeloma is likely to be further exarcebated by binding, internalizing, and degrading of OPG by tumor cells [20].
OPG Spec (likely) Binding (binding) of in bone marrow associated with cancer
5) Confidence 0.30 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924519 Disease Relevance 0.66 Pain Relevance 0.11
In this model, activated T cells express RANKL protein on their surface, and through binding of RANKL to RANK on preosteoclasts, these cells promote osteoclastogenesis and subsequent bone loss.
RANKL Binding (binding) of in T cells
6) Confidence 0.29 Published 2001 Journal Arthritis Res Section Body Doc Link PMC128900 Disease Relevance 1.40 Pain Relevance 0.60
As discussed above regarding the AIA model of inflammatory bone loss, T lymphocytes contribute to local bone loss by promoting osteoclastogenesis via RANKL-RANK interaction in the inflamed joint and surrounding bone marrow.
RANKL-RANK Binding (interaction) of in bone marrow associated with inflammation and arthritis
7) Confidence 0.29 Published 2001 Journal Arthritis Res Section Body Doc Link PMC128900 Disease Relevance 1.41 Pain Relevance 0.47
OPG inhibits bone resorption and binds with strong affinity to its ligand, RANKL, thereby preventing RANKL binding to its receptor, RANK [11,13,14].
OPG Binding (binds) of associated with hypercalcemia
8) Confidence 0.28 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1257432 Disease Relevance 1.02 Pain Relevance 0.38
Capsazepine inhibited osteoclast formation and bone resorption in a dose dependent manner in bone marrow-osteoblast co-cultures and RANKL generated osteoclast cultures, whereas the TRPV1 agonist capsaicin enhanced RANKL and M-CSF stimulated osteoclast formation.
RANKL Binding (formation) of in osteoclast associated with qutenza, agonist, osteoporosis and hypercalcemia
9) Confidence 0.27 Published 2010 Journal Bone Section Abstract Doc Link 20096813 Disease Relevance 1.08 Pain Relevance 0.34
This lymphocyte mediated osteoclastogenic effect was not due to RANKL, since addition of soluble RANKL to K?
RANKL Neg (not) Binding (addition) of in lymphocyte
10) Confidence 0.27 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1899087 Disease Relevance 0.07 Pain Relevance 0.03
Intriguingly, RANKL/RANK interactions also regulate T cell/dendritic cell communication, dendritic cell survival and lymphnode formation [35].
RANKL Binding (interactions) of in T cell
11) Confidence 0.24 Published 2005 Journal Immun Ageing Section Body Doc Link PMC1308846 Disease Relevance 1.18 Pain Relevance 0.16
In arthritis, osteoclast precursors that express RANK recognize RANKL through cell-to-cell interaction with osteoblasts/stromal cells, and differentiate into osteoclasts [50].
RANKL Binding (recognize) of in osteoblasts associated with arthritis
12) Confidence 0.24 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1257432 Disease Relevance 0.77 Pain Relevance 0.41
RANKL is a molecule with structural homologies to TNF?
RANKL Binding (molecule) of
13) Confidence 0.23 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1860063 Disease Relevance 0.74 Pain Relevance 0.36
Osteoprotegerin (OPG) is a natural decoy receptor that binds to RANK ligand and prevents its interaction with RANK [42].
OPG Neg (prevents) Binding (interaction) of
14) Confidence 0.23 Published 2000 Journal Arthritis Res Section Body Doc Link PMC129996 Disease Relevance 0.54 Pain Relevance 0.22
This effect is independent of RANKL/RANK interaction and is potentiated by IL-1.
RANKL Binding (interaction) of
15) Confidence 0.22 Published 2001 Journal Arthritis Res Section Body Doc Link PMC128900 Disease Relevance 0.87 Pain Relevance 0.31
OPG inhibits bone resorption and binds with strong affinity to its ligand, RANKL, thereby preventing RANKL binding to its receptor, RANK [11,13,14].
RANKL Binding (ligand) of associated with hypercalcemia
16) Confidence 0.22 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1257432 Disease Relevance 1.01 Pain Relevance 0.38
B ligand (RANKL) and can thus drive osteoclast formation [11,12].
RANKL Binding (ligand) of in osteoclast
17) Confidence 0.20 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1860063 Disease Relevance 0.37 Pain Relevance 0.18
The interaction between RANKL and its receptor RANK on the surface of hemopoietic precursors and mature osteoclasts may induce both osteoclast precursor differentiation and mature osteoclast activation [12, 13].
RANKL Binding (interaction) of in osteoclast
18) Confidence 0.17 Published 2008 Journal J Orthop Traumatol Section Body Doc Link PMC2657328 Disease Relevance 0.34 Pain Relevance 0.17
B activation via the canonical pathway [32], and a synergistic interaction between RANKL and TNF may account for the pathological osteoclastogenesis seen in RA [33,34].
RANKL Binding (interaction) of associated with rheumatoid arthritis
19) Confidence 0.17 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592787 Disease Relevance 0.22 Pain Relevance 0.05
B ligand (RANKL), which in turn activates the TRAF6, c-Fos, and the NFATc1 pathway (Ishida et al., 2002; Takayanagi, 2002, 2005a).
RANKL Binding (ligand) of
20) Confidence 0.14 Published 2010 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2839155 Disease Relevance 0.65 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox